Payment overview · 2025
General Payments
$2,237.10
150 reported records · 20 companies
Healthcare provider profile · identity verified
Seth M Barnes, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HOT SPRINGS, AR · NPI 1417958919
Verified facts
What the public records show
CMS Open Payments records show Seth M Barnes, MD received $2,237.10 in general payments during 2025 across 150 reported records.
ABBVIE INC. accounted for 16.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 32 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Linzess, Mounjaro, Ozempic, Rexulti, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 62 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Ozempic by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 163 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $362.49 | 16.2% | 37 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $296.87 | 13.3% | 16 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $269.80 | 12.1% | 17 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $213.76 | 9.6% | 15 | 2025 |
| Viatris Specialty LLC | Unresolved — no canonical attribution shown | $140.27 | 6.3% | 11 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $140.13 | 6.3% | 10 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $113.13 | 5.1% | 5 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $103.27 | 4.6% | 5 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $97.47 | 4.4% | 5 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $85.88 | 3.8% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $77.80 | 3.5% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $70.36 | 3.1% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $58.91 | 2.6% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $52.05 | 2.3% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.49 | 2.2% | 3 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $28.41 | 1.3% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $23.10 | 1.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $20.17 | 0.9% | 1 | 2025 |
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $19.78 | 0.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $14.96 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,237.10 | 150 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $321.85 | 20 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $231.37 | 21 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $199.84 | 19 | 2025 |
Source payment records
|
|||||
| YUPELRI Normalized: yupelri |
Drug | Viatris Specialty LLC | $140.27 | 11 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $133.53 | 7 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $114.45 | 7 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $114.45 | 7 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $113.07 | 8 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $113.07 | 8 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $103.27 | 5 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $97.47 | 5 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $97.12 | 5 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $88.17 | 4 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $87.76 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $85.88 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $77.80 | 5 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $70.36 | 5 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $70.36 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $66.39 | 10 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $65.47 | 6 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $58.91 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $48.49 | 3 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $28.41 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $27.75 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $27.75 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $27.06 | 2 | 2025 |
Source payment records
|
|||||
| CARDIOMEMS Normalized: cardiomems |
Device | Abbott Laboratories | $24.96 | 1 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $23.10 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $20.17 | 1 | 2025 |
Source payment records
|
|||||
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $19.78 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $14.96 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 163 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 18 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 62 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 145 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 66 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
78 | 23 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
62 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
145 | 31 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
163 | 36 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 761 | 234 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 717 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 631 | 178 |
| Omeprazole | Omeprazole | 620 | 170 |
| Amlodipine Besylate | Amlodipine Besylate | 592 | 170 |
| Losartan Potassium | Losartan Potassium | 517 | 150 |
| Lisinopril | Lisinopril | 471 | 147 |
| Clonazepam | Clonazepam | 428 | 68 |
| Alprazolam | Alprazolam | 403 | 62 |
| Hydrochlorothiazide | Hydrochlorothiazide | 376 | 117 |
| Meloxicam | Meloxicam | 324 | 90 |
| Gabapentin | Gabapentin | 319 | 81 |
| Metformin Hcl | Metformin Hcl | 309 | 86 |
| Simvastatin | Simvastatin | 303 | 89 |
| Zolpidem Tartrate | Zolpidem Tartrate | 280 | 59 |
| Pantoprazole Sodium | Pantoprazole Sodium | 278 | 79 |
| Trazodone Hcl | Trazodone Hcl | 270 | 70 |
| Potassium Chloride | Potassium Chloride | 268 | 73 |
| Tramadol Hcl | Tramadol Hcl | 263 | 50 |
| Escitalopram Oxalate | Escitalopram Oxalate | 258 | 71 |
| Pravastatin Sodium | Pravastatin Sodium | 233 | 57 |
| Metoprolol Succinate | Metoprolol Succinate | 219 | 70 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 213 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 212 | 56 |
| Furosemide | Furosemide | 204 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 198 | 50 |
| Carvedilol | Carvedilol | 193 | 45 |
| Tamsulosin Hcl | Tamsulosin Hcl | 193 | 60 |
| Duloxetine Hcl | Duloxetine Hcl | 191 | 47 |
| Ezetimibe | Ezetimibe | 190 | 55 |
| Lorazepam | Lorazepam | 170 | 32 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 168 | 23 |
| Eliquis | Apixaban | 163 | 36 |
| Pregabalin | Pregabalin | 156 | 38 |
| Sertraline Hcl | Sertraline Hcl | 155 | 38 |
| Ozempic | Semaglutide | 145 | 31 |
| Allopurinol | Allopurinol | 137 | 34 |
| Clopidogrel | Clopidogrel Bisulfate | 135 | 37 |
| Tizanidine Hcl | Tizanidine Hcl | 128 | 30 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 107 | 29 |
| Montelukast Sodium | Montelukast Sodium | 104 | 29 |
| Famotidine | Famotidine | 99 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 95 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 92 | 35 |
| Metformin Hcl Er | Metformin Hcl | 89 | 24 |
| Prednisone | Prednisone | 89 | 26 |
| Fluoxetine Hcl | Fluoxetine Hcl | 86 | 23 |
| Ropinirole Hcl | Ropinirole Hcl | 85 | 24 |
| Finasteride | Finasteride | 83 | 24 |
| Glipizide | Glipizide | 81 | 23 |
| Carisoprodol | Carisoprodol | 80 | 16 |
| Temazepam | Temazepam | 79 | 15 |
| Synthroid | Levothyroxine Sodium | 78 | 23 |
| Clonidine Hcl | Clonidine Hcl | 76 | 20 |
| Oxycodone Hcl | Oxycodone Hcl | 76 | 11 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 76 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 75 | 21 |
| Citalopram Hbr | Citalopram Hydrobromide | 74 | 21 |
| Warfarin Sodium | Warfarin Sodium | 74 | 12 |
| Spironolactone | Spironolactone | 73 | 21 |
| Atenolol | Atenolol | 71 | 23 |
| Estradiol | Estradiol | 71 | 18 |
| Ondansetron Odt | Ondansetron | 70 | 22 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 67 | 22 |
| Promethazine Hcl | Promethazine Hcl | 66 | 14 |
| Quetiapine Fumarate | Quetiapine Fumarate | 66 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 66 | 16 |
| Januvia | Sitagliptin Phosphate | 65 | 15 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 65 | 13 |
| Celecoxib | Celecoxib | 62 | 19 |
| Jardiance | Empagliflozin | 62 | 13 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 60 | 11 |
| Donepezil Hcl | Donepezil Hcl | 60 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 60 | 15 |
| Alendronate Sodium | Alendronate Sodium | 55 | 15 |
| Xarelto | Rivaroxaban | 55 | 16 |
| Bupropion Xl | Bupropion Hcl | 54 | suppressed |
| Azithromycin | Azithromycin | 53 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 52 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 51 | 16 |
| Meclizine Hcl | Meclizine Hcl | 50 | 14 |
| Amitriptyline Hcl | Amitriptyline Hcl | 49 | 13 |
| Diazepam | Diazepam | 49 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 45 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 42 | 12 |
| Fentanyl | Fentanyl | 41 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 40 | 15 |
| Glimepiride | Glimepiride | 40 | suppressed |
| Mirtazapine | Mirtazapine | 40 | suppressed |
| Gemfibrozil | Gemfibrozil | 39 | suppressed |
| Sucralfate | Sucralfate | 38 | 12 |
| Fenofibrate | Fenofibrate | 37 | suppressed |
| Linzess | Linaclotide | 37 | suppressed |
| Mounjaro | Tirzepatide | 37 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Trulicity | Dulaglutide | 37 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | 12 |
| Nifedipine Er | Nifedipine | 34 | suppressed |
| Eszopiclone | Eszopiclone | 32 | suppressed |
| Lansoprazole | Lansoprazole | 32 | suppressed |
| Levofloxacin | Levofloxacin | 32 | 25 |
| Methadone Hcl | Methadone Hcl | 32 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 31 | 11 |
| Baclofen | Baclofen | 30 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 30 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 30 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 30 | suppressed |
| Nystatin | Nystatin | 29 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 29 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Naproxen | Naproxen | 28 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Metronidazole | Metronidazole | 27 | 15 |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Premarin | Estrogens, Conjugated | 26 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 25 | suppressed |
| Klor-Con M20 | Potassium Chloride | 25 | 15 |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Aripiprazole | Aripiprazole | 24 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 24 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 16 |
| Glipizide Er | Glipizide | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Mupirocin | Mupirocin | 24 | 15 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 24 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Acyclovir | Acyclovir | 23 | 12 |
| Fenofibrate | Fenofibrate,micronized | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 13 |
| Bumetanide | Bumetanide | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Levetiracetam | Levetiracetam | 22 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 22 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Lovastatin | Lovastatin | 21 | suppressed |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | 11 |
| Myrbetriq | Mirabegron | 20 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Rexulti | Brexpiprazole | 20 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 20 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 20 | suppressed |
| Topiramate | Topiramate | 20 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Methocarbamol | Methocarbamol | 19 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Methylprednisolone | Methylprednisolone | 18 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 15 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 15 | suppressed |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 15 | suppressed |
| Lactulose | Lactulose | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 15 | suppressed |
| Risperidone | Risperidone | 15 | suppressed |
| Verapamil Er | Verapamil Hcl | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 13 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 13 | suppressed |
| Lamotrigine | Lamotrigine | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Valsartan | Valsartan | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 12 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Juluca | Dolutegravir/Rilpivirine | 12 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Nitroglycerin | Nitroglycerin | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 12 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 12 | suppressed |
| Torsemide | Torsemide | 12 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,237.10 · 150 records | ABBVIE INC. | AIRSUPRA, Auvelity, BREZTRI, CAPLYTA, CARDIOMEMS, CREON, Cologuard Collection Kit, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, Senza, TRELEGY ELLIPTA, TZIELD, UBRELVY, VRAYLAR, Wegovy, XIFAXAN, YUPELRI, ZENPEP, ZEPBOUND | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error